Biography for Suzanne Elvidge
Suzanne Elvidge has been involved in biopharma science and business publishing and journalism for over twenty years. She became the editor of FierceBiomarkers in November 2011, and has also written for FierceVaccines and FierceDrugDelivery. As a freelance writer she has written news and features for a range of online and print publications including European Life Science, the Journal of Life Sciences (now the Burrill Report), In Vivo, Life Science Leader, Nature Biotechnology, PR Week and Start-Up. She is also the editor of Genome Engineering, a blog that monitors the latest developments in genome engineering. She lives in the Peak District, in a very rural part of Derbyshire, U.K., with her second-hand bookseller husband and two second-hand cats. She can be reached at email@example.com. Follow @suzannewriter on Twitter.
- Contact Suzanne
- Follow Suzanne on Google+
Articles by Suzanne Elvidge
The World Health Organization has declared this week to be World Immunization Week.
In Nigeria, around 3.3 million people were living with HIV/AIDS in 2010. To try to combat this, the country is kick-starting its vaccine program again.
Researchers in the U.S. and Australia have found that salmonella bacteria have the capacity to overwhelm vaccines.
A microemulsion vaccine carrier, developed by U.S. Army Maj. Jean M. Muderhwa and presented at Experimental Biology 2012, has the potential to improve the stability of vaccines.
Another site in the U.S. has begun recruiting for a Phase II clinical trial of Northwest Biotherapeutics' DCVax-L personalized brain cancer vaccine for the treatment of glioblastoma multiforme.
In the first large, population-based randomized controlled trial of the effectiveness of text message vaccine reminders, parents getting a reminder were more likely to take their kids for a flu shot.
Shingles can lead to post-herpetic pain and other issues in older people, and the vaccine, which halves the chance of severe attacks of shingles, is safe and well-tolerated in this group, a new study finds.
Phase II data for Agenus' HSPPC-96 vaccine (also known as vitespen) showed glioblasoma patients living longer, which could offer a glimmer of hope.
Scripps Research Institute is developing a passive vaccine to treat cocaine overdose and has seen promising results in animals.